CareDx, Inc. completed its acquisition of Naveris, Inc. on 2026-07-01, according to the Form 8-K CareDx, Inc. filed with the SEC on 2026-07-07. The filing states a price of $171.7 million.
| Acquirer | CareDx, Inc. |
|---|---|
| Acquired | Naveris, Inc. |
| Completed | 2026-07-01 |
| Price stated in the filing | $171.7 million |
| Reported by | CareDx, Inc. (CDNA), the buyer |
| Filing | Form 8-K, filed 2026-07-07 |
Want the whole picture on CareDx, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on CareDx, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CareDx, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
Naveris Transaction On July 1, 2026, the Company and Nautilus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub"), completed the previously announced acquisition of Naveris, Inc., a Delaware corporation ("Naveris"), pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, Naveris, Inc., Nautilus, Merger Sub, and Shareholder Representative Services LLC, solely in its capacity as the representative of the securityholders of Naveris.
The price, in the filing's words
The aggregate purchase price received by the Company was $171.7 million in cash, subject to certain customary adjustments specified in the Purchase Agreement for working capital, cash and indebtedness.
More from the filing
Eurobio Transaction On June 30, 2026, CareDx, Inc. (the "Company") completed the previously announced sale of the shares of CareDx AB, a wholly-owned Swedish subsidiary of the Company, and certain assets relating to the Company's kitted laboratory products business and related software to Eurobio Scientific S.A. ("Eurobio"), pursuant to and subject to the terms and conditions of the Purchase Agreement (the "Purchase Agreement"), by and between the Company and Eurobio (the "Eurobio Transaction").
Pursuant to, and subject to the terms and conditions set forth in, the Merger Agreement, Merger Sub merged with and into Naveris, with Naveris continuing as the surviving corporation and a wholly owned subsidiary of the Company (the "Naveris Transaction").
The aggregate purchase price paid by the Company consisted of $161.8 million in cash, subject to certain customary adjustments specified in the Merger Agreement for Naveris' cash, indebtedness, transaction expenses and net working capital.
Quoted from CareDx, Inc.'s Form 8-K; also reported in Form 8-K/A of 2026-09-16.
This is the only completed acquisition CareDx, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on CareDx, Inc.Look up CareDx, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.